US4438032A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Unique T-lymphocyte line and products derived therefrom
Assignee: University of California, San Diego
•
Filing: 1983-01-06
•
Granted: 1984-03-20
•
Expires: 2003-01-06
Abstract
Abstract Human T-lymphoblast cell line, Proteinaceous products produced therefrom, messenger RNA and DNA expressing the proteinaceous products. A human T-lymphoblast cell line (Mo) maintained as a continuous culture constitutively produces proteins, including immune interferon, neutrophil migration inhibition factor, granulocyte-macrophage colony-stimulating activity and erythroid-potentiating activity, as well as other proteins produced by T-cells.
Inventors
- 👤 David W. Golde
- 👤 Shirley G. Quan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:36
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/53; C07K14/555; C07K14/57; C07K14/81; C07K14/8107; C07K14/8146; C12; C12N; C12N15/00; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/827; Y10S530/837; Y10S530/838
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
43 words
A method for producing in isolatable amounts an excretory protein produced by a T-lymphocyte, said method comprising: cultivating as a single cell suspension the Mo cell line in a nutrient medium, whereby said excretory proteins are produced and excreted into said nutrient medium.
Claim 2
Independent Claim
43 words
A method for producing in isolatable amounts an excretory protein produced by a T-lymphocyte, said method comprising: cultivating as a single cell suspension the Mo cell line in a nutrient medium, whereby said excretory proteins are produced and excreted into said nutrient medium.
Claim 3
Dependent Claim
36 words
A method according to claim 1, wherein at least one of said proteins is a member of the group consisting of colony stimulating factor, erythroid potentiating factor, neutrophil migration inhibition factor and immune interferon Type II.
Claim 4
Dependent Claim
14 words
A method according to claim 2, wherein said protein is immune interferon, Type II.
Claim 5
Dependent Claim
13 words
A method according to claim 2, wherein said protein is colony stimulating factor.
Claim 6
Dependent Claim
13 words
A method according to claim 2, wherein said protein is erythroid potentiating factor
Claim 7
Dependent Claim
14 words
A method according to claim 2, wherein said protein is neutrophil migration inhibition factor.
Claim 8
Independent Claim
19 words
A method according to claims 3, 4, 5, or 6, including the step of isolating and purifying said protein.
Claim 9
Independent Claim
80 words
A method for cloning DNA including a gene capable of expressing a protein product produced by a T-lymphocyte, said method comprising: isolating messenger RNA from Mo cells; separating the messenger RNA coding for expression for a predetermined polypeptide from other messenger RNA; generating cDNA with reverse transcriptase from said messenger RNA; preparing double-stranded DNA from said cDNA employing DNA polymerase; inserting said double-stranded DNA into a vector; and transforming a host with said vector, whereby said double-stranded DNA is cloned.
Claim 10
Independent Claim
80 words
A method for cloning DNA including a gene capable of expressing a protein product produced by a T-lymphocyte, said method comprising: isolating messenger RNA from Mo cells; separating the messenger RNA coding for expression for a predetermined polypeptide from other messenger RNA; generating cDNA with reverse transcriptase from said messenger RNA; preparing double-stranded DNA from said cDNA employing DNA polymerase; inserting said double-stranded DNA into a vector; and transforming a host with said vector, whereby said double-stranded DNA is cloned.
Claim 11
Dependent Claim
36 words
A method according to claim 8, wherein said double stranded DNA is inserted into said vector to provide expression of said double-stranded DNA; and including the additional step of isolating protein expressed by said double-stranded DNA.
Claim 12
Dependent Claim
14 words
A method according to claim 9, wherein said protein is immune interferon, Type II.
Claim 13
Dependent Claim
13 words
A method according to claim 9, wherein said protein is erythroid potentiating factor.
Claim 14
Dependent Claim
13 words
A method according to claim 9, wherein said protein is colony stimulating factor.
Claim 15
Dependent Claim
14 words
A method according to claim 10, wherein said protein is neutrophil migration inhibition factor.
Claim 16
Dependent Claim
16 words
A protein composition comprising erythroid potentiating factor in an amount of at least about 50,000 units/mg.
Claim 17
Dependent Claim
16 words
A protein composition comprising erythroid potentiating factor in an amount of at least about 50,000 units/mg.
Claim 18
Dependent Claim
18 words
A protein composition comprising colony stimulating factor in an amount sufficient to provide at least about 10 units/mg.
Claim 19
Dependent Claim
18 words
A protein composition comprising colony stimulating factor in an amount sufficient to provide at least about 10 units/mg.
Claim 20
Dependent Claim
13 words
A single cell suspension of the Mo cell line in a nutrient medium.
Claim 21
Dependent Claim
13 words
A single cell suspension of the Mo cell line in a nutrient medium.
Claim 22
Dependent Claim
15 words
A single cell suspension according to claim 16, wherein said nutrient medium is serum free.
Claim 23
Dependent Claim
14 words
A single cell suspension according to claim 16, wherein said nutrient medium contains serum.
Claim 24
Dependent Claim
17 words
A genetic library comprising DNA fragments derived by restriction cleavage of DNA from the Mo cell line.
Claim 25
Dependent Claim
17 words
A genetic library comprising DNA fragments derived by restriction cleavage of DNA from the Mo cell line.
Claim 26
Dependent Claim
31 words
A method for stimulating the poliferation of human bone marrow cells, which comprises contacting said bone marrow cells an amount sufficient to cause proliferation of a composition according to claim 4.
Claim 27
Dependent Claim
34 words
A method for stimulating the proliferation of erythrocytes which comprises contacting human bone marrow cells in the presence of erythropoietin with a composition according to claim 5 in an amount sufficient to cause proliferation.
Claim 28
Dependent Claim
32 words
A method for inhibiting viral lysis of a human cell susceptible to viral lysis which comprises applying an inhibiting amount to a host human cell of a composition according to claim 3.
References Cited (Backward Citations)
US4338397A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-03-20 | 1987-09-19 | 1988-03-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-03-20 | 1991-09-19 | 1992-03-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-03-20 | 1995-09-19 | 1996-03-20 | $7700.00 | Window Closed / Lapsed |